Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-3)

Sum=0

Aug 15, 2024 (publication date) through Aug 7, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3521-3528
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3521

Table 2 Tumor response to first-line chemotherapy containing bevacizumab, n (%)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Disease progression.

Citation: Kang SW, Lim SH, Kim MJ, Lee J, Park YS, Lim HY, Kang WK, Kim ST. Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1. World J Gastrointest Oncol 2024; 16(8): 3521-3528
URL: https://www.wjgnet.com/1948-5204/full/v16/i8/3521.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i8.3521